Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: Occurrence of leukaemic evolution

Vitaliana De Sanctis, Maria Gabriella Mazzucconi, Antonio Spadea, Marco Alfò, Marco Mancini, Luisa Bizzoni, Monica Peraino, Franco Mandelli

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Essential thrombocythaemia (ET) is usually considered an indolent disease, but it may progress during its natural course into acute leukaemia (AL); however, an influence of myelosuppressive agents in the blastic transformation of ET cannot be excluded. We performed a retrospective study to assess the incidence of AL in ET patients treated with pipobroman (PB) as first-line therapy. One hundred and sixty-four patients with ET were managed with PB at a dose of 1 mg/kg/d until a stable platelet count below 400 x 109/l was achieved. Maintenance therapy was given at a planned dose ranging between 0.2 and 1 mg/kg/d according to platelet count, in all cases, with a median daily dose of 25 mg (range 7-75 mg/d). The median treatment time was 100 months (range 25-243 months). The patients were evaluated for the occurrence of AL and/or secondary malignancies and survival end-points. AL was observed in nine patients (5.5%) after a median treatment time of 153 months (range 79-227 months). The overall survival (OS) and the event-free survival (EFS) at 120 months were 95% and 97%, whereas at 180 months, they were 84% and 76% respectively. In conclusion, this retrospective analysis shows a low incidence of AL in a large group of patients consecutively treated with PB as first-line chemotherapy. Therefore, an investigation of the role of myelosuppressive agents in the blastic transformation of ET would be of interest.

Original languageEnglish
Pages (from-to)517-521
Number of pages5
JournalBritish Journal of Haematology
Volume123
Issue number3
DOIs
Publication statusPublished - Nov 2003

Fingerprint

Pipobroman
Essential Thrombocythemia
Leukemia
Platelet Count
Survival
Incidence
Therapeutics
Disease-Free Survival
Retrospective Studies
Drug Therapy

Keywords

  • Essential thrombocythaemia
  • Leukaemic evolution
  • Myeloproliferative disorders
  • Pipobroman

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman : Occurrence of leukaemic evolution. / De Sanctis, Vitaliana; Mazzucconi, Maria Gabriella; Spadea, Antonio; Alfò, Marco; Mancini, Marco; Bizzoni, Luisa; Peraino, Monica; Mandelli, Franco.

In: British Journal of Haematology, Vol. 123, No. 3, 11.2003, p. 517-521.

Research output: Contribution to journalArticle

De Sanctis, Vitaliana ; Mazzucconi, Maria Gabriella ; Spadea, Antonio ; Alfò, Marco ; Mancini, Marco ; Bizzoni, Luisa ; Peraino, Monica ; Mandelli, Franco. / Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman : Occurrence of leukaemic evolution. In: British Journal of Haematology. 2003 ; Vol. 123, No. 3. pp. 517-521.
@article{1938bb999f5142b1926519bd4ea6a76e,
title = "Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: Occurrence of leukaemic evolution",
abstract = "Essential thrombocythaemia (ET) is usually considered an indolent disease, but it may progress during its natural course into acute leukaemia (AL); however, an influence of myelosuppressive agents in the blastic transformation of ET cannot be excluded. We performed a retrospective study to assess the incidence of AL in ET patients treated with pipobroman (PB) as first-line therapy. One hundred and sixty-four patients with ET were managed with PB at a dose of 1 mg/kg/d until a stable platelet count below 400 x 109/l was achieved. Maintenance therapy was given at a planned dose ranging between 0.2 and 1 mg/kg/d according to platelet count, in all cases, with a median daily dose of 25 mg (range 7-75 mg/d). The median treatment time was 100 months (range 25-243 months). The patients were evaluated for the occurrence of AL and/or secondary malignancies and survival end-points. AL was observed in nine patients (5.5{\%}) after a median treatment time of 153 months (range 79-227 months). The overall survival (OS) and the event-free survival (EFS) at 120 months were 95{\%} and 97{\%}, whereas at 180 months, they were 84{\%} and 76{\%} respectively. In conclusion, this retrospective analysis shows a low incidence of AL in a large group of patients consecutively treated with PB as first-line chemotherapy. Therefore, an investigation of the role of myelosuppressive agents in the blastic transformation of ET would be of interest.",
keywords = "Essential thrombocythaemia, Leukaemic evolution, Myeloproliferative disorders, Pipobroman",
author = "{De Sanctis}, Vitaliana and Mazzucconi, {Maria Gabriella} and Antonio Spadea and Marco Alf{\`o} and Marco Mancini and Luisa Bizzoni and Monica Peraino and Franco Mandelli",
year = "2003",
month = "11",
doi = "10.1046/j.1365-2141.2003.04542.x",
language = "English",
volume = "123",
pages = "517--521",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman

T2 - Occurrence of leukaemic evolution

AU - De Sanctis, Vitaliana

AU - Mazzucconi, Maria Gabriella

AU - Spadea, Antonio

AU - Alfò, Marco

AU - Mancini, Marco

AU - Bizzoni, Luisa

AU - Peraino, Monica

AU - Mandelli, Franco

PY - 2003/11

Y1 - 2003/11

N2 - Essential thrombocythaemia (ET) is usually considered an indolent disease, but it may progress during its natural course into acute leukaemia (AL); however, an influence of myelosuppressive agents in the blastic transformation of ET cannot be excluded. We performed a retrospective study to assess the incidence of AL in ET patients treated with pipobroman (PB) as first-line therapy. One hundred and sixty-four patients with ET were managed with PB at a dose of 1 mg/kg/d until a stable platelet count below 400 x 109/l was achieved. Maintenance therapy was given at a planned dose ranging between 0.2 and 1 mg/kg/d according to platelet count, in all cases, with a median daily dose of 25 mg (range 7-75 mg/d). The median treatment time was 100 months (range 25-243 months). The patients were evaluated for the occurrence of AL and/or secondary malignancies and survival end-points. AL was observed in nine patients (5.5%) after a median treatment time of 153 months (range 79-227 months). The overall survival (OS) and the event-free survival (EFS) at 120 months were 95% and 97%, whereas at 180 months, they were 84% and 76% respectively. In conclusion, this retrospective analysis shows a low incidence of AL in a large group of patients consecutively treated with PB as first-line chemotherapy. Therefore, an investigation of the role of myelosuppressive agents in the blastic transformation of ET would be of interest.

AB - Essential thrombocythaemia (ET) is usually considered an indolent disease, but it may progress during its natural course into acute leukaemia (AL); however, an influence of myelosuppressive agents in the blastic transformation of ET cannot be excluded. We performed a retrospective study to assess the incidence of AL in ET patients treated with pipobroman (PB) as first-line therapy. One hundred and sixty-four patients with ET were managed with PB at a dose of 1 mg/kg/d until a stable platelet count below 400 x 109/l was achieved. Maintenance therapy was given at a planned dose ranging between 0.2 and 1 mg/kg/d according to platelet count, in all cases, with a median daily dose of 25 mg (range 7-75 mg/d). The median treatment time was 100 months (range 25-243 months). The patients were evaluated for the occurrence of AL and/or secondary malignancies and survival end-points. AL was observed in nine patients (5.5%) after a median treatment time of 153 months (range 79-227 months). The overall survival (OS) and the event-free survival (EFS) at 120 months were 95% and 97%, whereas at 180 months, they were 84% and 76% respectively. In conclusion, this retrospective analysis shows a low incidence of AL in a large group of patients consecutively treated with PB as first-line chemotherapy. Therefore, an investigation of the role of myelosuppressive agents in the blastic transformation of ET would be of interest.

KW - Essential thrombocythaemia

KW - Leukaemic evolution

KW - Myeloproliferative disorders

KW - Pipobroman

UR - http://www.scopus.com/inward/record.url?scp=0242266434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242266434&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04542.x

DO - 10.1046/j.1365-2141.2003.04542.x

M3 - Article

C2 - 14617017

AN - SCOPUS:0242266434

VL - 123

SP - 517

EP - 521

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -